Steven Diamantis, MD
Interventional Cardiology · Omaha, NENPI 1972564961
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,795 and has fallen 91.0% since, to $161 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NE, where the typical reported total is $6,648.
Across 373 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$882
- Abbott$804
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$423
- Pfizer$387
- Boehringer Ingelheim$358
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,39899%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 78 | $1,044 |
| Amgen | 51 | $882 |
| Abbott | 10 | $804 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $423 |
| Pfizer | 25 | $387 |
| Boehringer Ingelheim | 23 | $358 |
| E.r. Squibb & Sons, L.L.C. | 15 | $292 |
| Sanofi-aventis U.S. LLC | 18 | $281 |
| Johnson & Johnson | 18 | $266 |
| Boston Scientific | 9 | $231 |
| AstraZeneca | 16 | $205 |
| Esperion Therapeutics, Inc. | 12 | $178 |
| Amarin Pharma, Inc. | 10 | $177 |
| Actelion Pharmaceuticals US, Inc. | 7 | $147 |
| Merck | 6 | $92 |
| Regeneron Healthcare Solutions, Inc. | 5 | $79 |
| Bayer | 2 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Abiomed | 2 | $50 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Itamar Medical Inc | 1 | $35 |
| Impulse Dynamics (USA) Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Sanofi | 1 | $27 |
| Portola Pharmaceuticals, LLC | 1 | $26 |
| Medtronic | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Zimmer Biomet | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Penumbra, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$501
- Quadra Assura CRT Defibrillator$214
- Repatha$125
How this compares
$6,435 in reported general payments places this provider in the 45th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 382 | $333,435 |
| EntrestoSacubitril/Valsartan | 206 | $202,902 |
| Repatha SureclickEvolocumab | 122 | $103,256 |
| XareltoRivaroxaban | 49 | $48,578 |
| Praluent PenAlirocumab | 64 | $37,242 |
| BrilintaTicagrelor | 36 | $23,088 |
| VerquvoVericiguat | 23 | $16,498 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $9,896 |
| VascepaIcosapent Ethyl | 13 | $8,848 |
| EdarbiAzilsartan Medoxomil | 15 | $7,347 |
| JardianceEmpagliflozin | 12 | $7,212 |
| Valsartan | 291 | $5,404 |
| Metoprolol Succinate | 422 | $4,549 |
| Ezetimibe | 294 | $4,345 |
| Atorvastatin Calcium | 441 | $3,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $387 | $333,435382 claims |
| NovartisEntresto | $1,044 | $202,902206 claims |
| Johnson & JohnsonXarelto | $266 | $48,57849 claims |
| AstraZenecaBrilinta | $205 | $23,08836 claims |
| MerckVerquvo | $92 | $16,49823 claims |
| Esperion Therapeutics, Inc.Nexlizet | $178 | $9,89615 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $50 | $7,34715 claims |
| Boehringer IngelheimJardiance | $358 | $7,21212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.